BDMD vs. CATX, AMRN, SGMO, ABEO, RCEL, ARAY, TVGN, PROF, GOSS, and SERA
Should you be buying Baird Medical Investment stock or one of its competitors? The main competitors of Baird Medical Investment include Perspective Therapeutics (CATX), Amarin (AMRN), Sangamo Therapeutics (SGMO), Abeona Therapeutics (ABEO), AVITA Medical (RCEL), Accuray (ARAY), Tevogen Bio (TVGN), Profound Medical (PROF), Gossamer Bio (GOSS), and Sera Prognostics (SERA). These companies are all part of the "medical" sector.
Baird Medical Investment vs.
Perspective Therapeutics (NYSE:CATX) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.
Baird Medical Investment has lower revenue, but higher earnings than Perspective Therapeutics.
Perspective Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Baird Medical Investment has a beta of -0.68, suggesting that its stock price is 168% less volatile than the S&P 500.
Perspective Therapeutics presently has a consensus price target of $15.14, indicating a potential upside of 320.63%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Perspective Therapeutics is more favorable than Baird Medical Investment.
Perspective Therapeutics received 20 more outperform votes than Baird Medical Investment when rated by MarketBeat users.
54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by insiders. Comparatively, 78.9% of Baird Medical Investment shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Baird Medical Investment had 4 more articles in the media than Perspective Therapeutics. MarketBeat recorded 10 mentions for Baird Medical Investment and 6 mentions for Perspective Therapeutics. Perspective Therapeutics' average media sentiment score of 0.60 beat Baird Medical Investment's score of 0.00 indicating that Perspective Therapeutics is being referred to more favorably in the media.
Baird Medical Investment has a net margin of 0.00% compared to Perspective Therapeutics' net margin of -4,096.66%. Baird Medical Investment's return on equity of 0.00% beat Perspective Therapeutics' return on equity.
Summary
Perspective Therapeutics beats Baird Medical Investment on 8 of the 13 factors compared between the two stocks.
Get Baird Medical Investment News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Baird Medical Investment Competitors List
Related Companies and Tools
This page (NASDAQ:BDMD) was last updated on 1/23/2025 by MarketBeat.com Staff
